1. Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting
- Author
-
Som Akshay Jain, Arianna Gennari, Francesco Rosso, Manlio Barbarisi, Rosario Vincenzo Iaffaioli, Alfonso Barbarisi, Vincenzo Quagliariello, Nicola Tirelli, Quagliariello, Vincenzo, Gennari, Arianna, Akshay Jain, Som, Rosso, Francesco, Vincenzo Iaffaioli, Rosario, Barbarisi, Alfonso, Barbarisi, Manlio, and Tirelli, Nicola
- Subjects
Male ,Materials science ,medicine.medical_treatment ,Tumour targeting ,Bioengineering ,Mice, SCID ,Pharmacology ,Biomaterials ,Mice ,chemistry.chemical_compound ,Drug Delivery Systems ,Neoplasms ,LNCaP ,Hyaluronic acid ,medicine ,Animals ,Prodrugs ,Hyaluronic Acid ,Micelles ,Chemotherapy ,Cancer ,Prodrug ,medicine.disease ,chemistry ,Targeted drug delivery ,Mechanics of Materials ,Quercetin - Abstract
Hyaluronic acid (HA)-based prodrugs bearing double-responsive (acid pH or oxidation) boronates of catechol-containing drugs were used to treat xenografted human prostate tumours (LNCaP) in SCID mice. The HA prodrugs accumulated significantly only in tumours (impressively, up to 40% of the injected dose after 24 h) and in liver, with negligible – actually anti-inflammatory - consequences in the latter. A quercetin-HA prodrug significantly slowed down tumour growth, in a dose-dependent fashion and with a much higher efficacy (up to 4 times) than equivalent doses of free quercetin. In short, boronated HA appears to be a very promising platform for targeted chemotherapy.
- Published
- 2021
- Full Text
- View/download PDF